Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 300

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 300
---
losure or assignment agreement for
any reason, we may not own the invention or our intellectual property, and our products may not be adequately protected. Thus, we cannot
guarantee that our product candidates, or our commercialization thereof, does not and will not infringe any third party’s intellectual
property.

We
have been granted a license to the right to develop Telomir-1 in the United States in human and pet application, but we have not been
granted a license to the rights to patents covering Telomir-1 in foreign jurisdictions.

We
have been granted a license to the right to develop Telomir-1 in the United States but not in countries outside the United States, as
MIRALOGX has retained all rights outside the United States and may license such rights to other parties. Accordingly, MIRALOGX potentially
could develop a competing product for such jurisdictions outside of the United States.

Risks
Related to Our Operations and Financial Condition

We
are an early development-stage company with no revenues.

As
very early development-stage enterprise that is focused on the development of a pre-clinical pharmaceutical product, we have generated
no revenue and have an accumulated deficit of $30.6 million and $14.1 million as of December 31, 2024 and December 31, 2023, respectively.
There can be no assurance that sufficient funds required to pursue our development program will be generated from operations or that
funds will be available from external sources, such as debt or equity financings or other potential sources. The lack of additional capital
resulting from the inability to generate cash flow from operations, or to raise capital from external sources would force us to substantially
curtail or cease operations and would, therefore, have a material adverse effect on business. Furthermore, there can be no assurance
that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect
on our existing stockholders. It is for these reasons substantial doubt about our ability to continue as a going concern exists and an
explanatory paragraph relating to our ability to continue as a going concern can be found within the report of our independent registered
public accounting firm on our audited financial statements for the fiscal year ended December 31, 2024.

We
seek to overcome the circumstances that impact our ability to remain a going concern in the future through the growth of revenues with
interim cash flow deficiencies being